Nuvalent, Inc. Class A (NUVL)

The FDA's acceptance of NDAs for zidesamtinib and neladalkib has positively impacted Nuvalent's stock. Positive data from the ARROS-1 and ALKOVE-1 clinical trials were presented at WCLC 2025 and ASCO 2026, respectively. A strategic collaboration with Guardant Health for oncology drug development was viewed positively. Nuvalent reported a wider net loss for Q1 2026 due to increased R&D expenses, but ended the quarter with $1.3 billion in cash, projected to fund operations into 2029. There has been a notable wave of insider selling in recent months.

Nuvalent does not have commercialized products and is not subject to demand seasonality. Its value is driven by R&D, clinical trials, regulatory milestones, and funding.

Nuvalent, Inc. is a clinical-stage biotechnology company in Cambridge, Massachusetts, focused on developing targeted therapies for cancer. They create small-molecule inhibitors for cancers with limitations in existing drugs, such as resistance mutations and CNS involvement. Key product candidates include NVL-520 (Zidesamtinib), a ROS1-selective inhibitor for ROS1-positive NSCLC, NVL-655 (Neladalkib), an ALK-selective inhibitor for ALK-positive cancers, and NVL-330, a brain-penetrant HER2-selective inhibitor. The company is pre-commercial, with economics driven by R&D, clinical data, regulatory execution, and capital discipline.

Nuvalent's headquarters are in Cambridge, Massachusetts, but its clinical trials are conducted internationally. The company also utilizes a global network of external development and manufacturing partners.

Nuvalent's brand reputation has been positively influenced by clinical development progress and regulatory achievements. Positive data from zidesamtinib and neladalkib at oncology conferences and FDA acceptance of NDAs have bolstered its reputation. The collaboration with Guardant Health also contributes positively. Insider selling activity could be perceived with caution by some investors.

Nuvalent has significant institutional ownership, with 238 institutional owners holding 78,963,673 shares. Major institutional owners include Deerfield Management Company, Fmr Llc, and Vanguard Group Inc. James E. Flynn is the largest individual shareholder, owning 17.90 million shares. Institutional shareholders hold 101.15% of Nuvalent stock, while insiders hold 29.42%.